https://scholars.lib.ntu.edu.tw/handle/123456789/608097
標題: | A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant | 作者: | Chang, Yi-Chung Yang, Chi-Fan Chen, Yi-Fen Yang, Chia-Chun Chou, Yuan-Lin Chou, Hung-Wen Chang, Tein-Yao TAI-LING CHAO Hsu, Shu-Chen Ieong, Si-Man Tsai, Ya-Min Liu, Ping-Cheng Chin, Yuan-Fan Fang, Jun-Tung Kao, Han-Chieh Lu, Hsuan-Ying Chang, Jia-Yu Weng, Ren-Shiuan Tu, Qian-Wen Chang, Fang-Yu Huang, Kuo-Yen Lee, Tong-Young SUI-YUAN CHANG PAN-CHYR YANG |
關鍵字: | COVID-19; K18-hACE2-transgenic mice; SARS-CoV-2; inhalation; siRNA | 公開日期: | 7-四月-2022 | 出版社: | WILEY | 卷: | 14 | 期: | 4 | 來源出版物: | EMBO molecular medicine | 摘要: | The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants has altered the trajectory of the COVID-19 pandemic and raised some uncertainty on the long-term efficiency of vaccine strategy. The development of new therapeutics against a wide range of SARS-CoV-2 variants is imperative. We, here, have designed an inhalable siRNA, C6G25S, which covers 99.8% of current SARS-CoV-2 variants and is capable of inhibiting dominant strains, including Alpha, Delta, Gamma, and Epsilon, at picomolar ranges of IC50 in vitro. Moreover, C6G25S could completely inhibit the production of infectious virions in lungs by prophylactic treatment, and decrease 96.2% of virions by cotreatment in K18-hACE2-transgenic mice, accompanied by a significant prevention of virus-associated extensive pulmonary alveolar damage, vascular thrombi, and immune cell infiltrations. Our data suggest that C6G25S provides an alternative and effective approach to combating the COVID-19 pandemic. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/608097 | ISSN: | 1757-4676 | DOI: | 10.15252/emmm.202115298 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。